Biobank for patients with aggressive tumors
Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study
This study is collecting blood and tumor samples from patients with aggressive cancers to see if they can find clues to create better, personalized treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 1 Year and up |
| Sex | All |
| Sponsor | N.N. Petrov National Medical Research Center of Oncology Academic / other |
| Locations | 1 site (Saint Petersburg) |
| Trial ID | NCT05539677 on ClinicalTrials.gov |
What this trial studies
This study aims to collect blood and tumor tissue samples from patients with various malignant solid tumors, including brain tumors, melanoma, soft tissue sarcoma, and colorectal cancer. The collected samples will be analyzed to assess immunological factors, including blood cell subpopulations and tumor-specific antigens, alongside clinical data such as treatment responses and patient demographics. The goal is to identify potential biomarkers that could help tailor treatment strategies for individual patients.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically verified solid tumors who are currently receiving systemic therapy and can provide biosamples.
Not a fit: Patients with concurrent lymphoproliferative disorders or those who have undergone stem cell or bone marrow transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with aggressive tumors.
How similar studies have performed: Other studies focusing on biomarker discovery in similar patient populations have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed inform consent * Histolgically verified solid tumour * Receiving systemic therapy for neoplasm * Has archival tumour tissue * Provide biosamples with living tumour tissue or blood samples for immunologic assessment Exclusion Criteria: * Concurrent Lymphoprolipherative disorder * Patients after stem cell or bone marrow thansplantation * Incomplete informaton on previous cancer history or medical history * Patients with known primary immunodeficiency * Patients receiving immunosupressive therapy for concurrent illness * Pregnant patients
Where this trial is running
Saint Petersburg
- N.N. Petrov NMRC of Oncology, Oncoimmunology dep. — Saint Petersburg, Russia (Recruiting)
Study contacts
- Study coordinator: Aleksei Novik, MD, PhD
- Email: alexey.viktorovich.novik@gmail.com
- Phone: +78124399505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.